Contrary to current clinical guidelines, new evidence suggests there is no value in the routine use of antacids in patients with idiopathic pulmonary fibrosis (IPF). Instead, the findings suggest reflux directed therapy should be considered on an individual basis. A study of 587 patients from the Australian IPF registry showed no clinical benefit from proton ...
Already a member?
Enter your email to keep reading.